Form 4: Senti Biosciences Executive Acquires Shares Through Conversion

Kanya Rajangam, a top executive at Senti Biosciences, acquired 33,000 shares of common stock through the conversion of Series A Convertible Preferred Stock.

Summary

• Kanya Rajangam, President & Chief Medical & Development Officer of Senti Biosciences, filed a Form 4 on March 11, 2025, reporting a transaction that occurred on March 10, 2025.
• Rajangam acquired 33,000 shares of common stock through the conversion of Series A Convertible Preferred Stock at a price of $2.25 per share.
• Following the transaction, Rajangam directly owns 86,984 shares of common stock.
• Rajangam also indirectly owns 33,000 shares of common stock and Series A Convertible Preferred Stock through the Iyer Family Revocable Trust dated August 26, 2012.
• Rajangam disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

• The transaction could have a minor impact on shareholders, as it increases the number of outstanding shares.

Key Dates